1	Title page
2	Title: β -arrestin-dependent ERK signaling positively correlates with reduced anxiety-like and
3	conditioned fear-related behavior in mice
4	
5	Authors: Mee Jung Ko ^{1,3,4} , Terrance Chiang ¹ , Arbaaz M. Mukadam ¹ , Grace E. Mulia ¹ , Anna
6	M. Gutridge ^{1,3} , Julia A. Chester ^{2,3,4} , Richard M. van Rijn ^{1,3,4,5‡*}
7	
8	Author footnotes:
9	¹ Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy,
10	Purdue University, West Lafayette, IN, 47907, USA
11	² Department of Psychological Sciences, College of Health and Human Sciences, Purdue
12	University, West Lafayette, IN, 47907, USA
13	³ Purdue Institute for Integrative Neuroscience, West Lafayette, IN, 47907, USA
14	⁴ Purdue Interdisciplinary Life Sciences Graduate Program, West Lafayette, IN, 47907, USA
15	⁵ Purdue Institute for Drug Discovery, West Lafayette, IN, 47907, USA
16	[‡] Lead Contact
17	*Correspondence: <u>rvanrijn@purdue.edu</u>
18	
19	
20	
21	
22	
23	
24	
25	

	I	

2

Summary

3 Exposure to anxiety- or fear-invoking stimuli initiate a convergence of executive actions 4 orchestrated by multiple proteins and neurotransmitters across the brain. Dozens of G 5 protein-coupled receptors (GPCRs) have been linked to regulation of fear and anxiety. GPCR 6 signaling involves canonical G protein pathways but may also engage downstream kinases 7 and effectors through β -arrestin scaffolds. Here, we investigate whether β -arrestin signaling 8 is critical for the emotional regulation of anxiety-like and fear-related behavior. Using the δ -9 opioid receptor (δOR) as a model GPCR, we found that β -arrestin 2-dependent activation of 10 extracellular signal-regulated kinases (ERK1/2) in the dorsal hippocampus and the amygdala 11 are critical for δ OR-induced anxiolytic-like effects. In contrast, G protein-mediated δ OR 12 signaling was associated with decreased ERK1/2 activity and increased fear-related behavior. 13 Our results also suggest a potential contribution of β -arrestin 1 in fear-reducing effects. 14 Overall, our findings highlight the significance of non-canonical β -arrestin signaling in the 15 regulation of emotions.

16

Key words: GPCR; β-arrestin isoforms; anxiety; fear conditioning; ERK1/2; biased signaling;
amygdala; dorsal hippocampus; nucleus accumbens; delta opioid receptor

- 19
- 20
- 21
- 22
- 23
- 24
- 25

4		
	I	
	L	
-	-	

2

3

Introduction

4 Anxiety- and fear-related behaviors are evolutionary adaptive behaviors important for 5 human survival. However, excessive stimulation of the neural circuits that regulate anxiety-6 and fear-related behaviors can lead to harmful psychiatric disorders. The expression of 7 anxiety- and fear-related behaviors is regulated by complex integration of both internal and 8 external physiological and sensory cues that influence reflexive behavior, cognitive control, 9 and executive functions. Accordingly, behavioral correlates of anxiety and fear are regulated 10 by a harmonious activity of neurotransmitters and cellular actions across many overlapping 11 and distinct neural circuits (Tovote et al., 2015).

12 With regard to cellular actions underlying (patho-)physiological behavior, G protein-13 coupled receptors (GPCRs) play an important role in neuronal signaling. GPCRs bind 14 neurotransmitters and initiate intracellular signal transduction pathways which ultimately 15 affect neuronal excitability, neurotransmitter release and synaptic plasticity. GPCRs, 16 including serotonergic (Akimova et al., 2009), dopaminergic (de la Mora et al., 2010), 17 adrenergic (Kindt et al., 2009), opioidergic (Land et al., 2009) and corticotropin-releasing 18 factor receptors (Takahashi, 2001) have well-documented roles in the modulation of anxiety 19 and fear.

Traditionally, drug development at GPCRs has focused on the canonical G protein pathways; however, the prior two decades have introduced arrestin-dependent signaling as a new concept of GPCR signal transduction. In particular, the 'non-visual' arrestins 2 and 3, referred here as β -arrestin 1 and 2, respectively, have been associated with specific and unique drug effects. The primary role of β -arrestins is to desensitize GPCRs, for example, HIV1-tat infection increases β -arrestin 2 expression in mice amygdala, leading to significant

1 reduction in morphine efficacy in this region (Hahn et al., 2016). Beyond desensitization, β -2 arrestin 2 may also partake in receptor signaling by scaffolding with various kinases. For 3 example, β -arrestin 2 p38 MAP kinase signaling has been linked to the aversive effects of κ -4 opioid receptor (κ OR) agonists (Bruchas et al., 2006; Land et al., 2009), whereas a β -arrestin 5 2-GSK3 β /AKT scaffold appears to be driving the antipsychotic effects of dopamine D₂ 6 receptors agonists (Allen et al., 2011; Beaulieu et al., 2005). Currently, few studies have 7 investigated how signaling scaffolds involving the β-arrestin isoforms may influence anxiety-8 and fear-like behavior. It is important to begin to address this gap in our current knowledge of 9 the GPCR modulation of psychiatric behavior, especially since the majority of medications 10 that target GPCRs were developed without consideration of the potential adverse or 11 therapeutic effects of β -arrestin signaling. Yet, it is now possible to develop molecules that 12 preferentially activate or avoid β -arrestin signaling and thus have the potential to treat 13 psychiatric disorders more effectively and with a wider therapeutic window.

14 Here, we describe our efforts to elucidate the roles of β -arrestin isoforms in mediating 15 GPCR signaling in relation to the modulation of anxiety and fear-like behavior. We chose to 16 utilize the δ -opioid receptor (δ OR) as a model GPCR. Previous studies have shown that the 17 δOR selective agonist SNC80 is an efficacious recruiter of β -arrestin 1 and 2 proteins 18 (Chiang et al., 2016; Pradhan et al., 2016; Vicente-Sanchez et al., 2018), and has anxiolytic-19 like (Saitoh et al., 2004; Saitoh et al., 2018) and fear-reducing effects (Li et al., 2009; Saitoh 20 et al., 2004). Moreover, the δ OR-selective agonist TAN67, which is a poor β -arrestin 2 21 recruiter does not reduce anxiety-like behavior in naïve mice (van Rijn et al., 2010), 22 providing further support for the correlation between β-arrestin 2 signaling and anxiety-like 23 behavior.

Mitogen activated protein kinases (MAPKs) have been implicated with mood
disorders and can scaffold with β-arrestin (Coyle and Duman, 2003; Lefkowitz and Shenoy,

1 2005). Studies have suggested that MAPK signaling, specifically ERK1/2, in the 2 hippocampus and the basolateral amygdala is required for the acquisition and extinction of 3 fear memory (Atkins et al., 1998; Herry et al., 2006). Therefore, we hypothesized that β -4 arrestin-dependent MAPK signaling may contribute to anxiety-like and fear-related behavior. 5 To test our hypothesis, we assessed the degree to which β -arrestin isoforms and MAPK 6 activation were involved in δOR agonist-mediated modulation of unconditioned anxiety-7 related behavior and cued-induced fear-related behavior. Our results suggest that ERK1/2 8 activity is differentially modulated by G protein and β -arrestin signaling and is correlated 9 with anxiety-like and fear-related responses in C57BL/6 mice. We noted that different β -10 arrestin isoforms were involved in the activation of ERK1/2 across various brain regions, 11 including the striatum, hippocampus and amygdala. 12 13 **Results** 14 Involvement of β -arrestin 2 in the modulation of anxiety-like behavior 15 In 2016, Astra Zeneca revealed that their novel δOR selective agonist AZD2327 (Fig. 1a, 16 Left) was capable of reducing anxiety-like behavior in mice (Richards et al., 2016). 17 AZD2327 is not commercially available, but is structurally similar to SNC80, a commercially 18 available δOR selective agonist (Fig. 1a, Right). SNC80 is a known super-recruiter of β -19 arrestin 2 (Chiang et al., 2016) (Fig. 1b) and similar to AZD2327 exhibits anxiolytic-like 20 effects in rodents (Saitoh et al., 2004; van Rijn et al., 2010). These previous findings led us 21 to hypothesize that β -arrestin 2 may be required for the anxiolytic effects of SNC80 and 22 AZD2327. Using two models of anxiety-like behavior, the elevated plus maze (EPM) test and 23 dark-light box transition test (Fig. 1c), we measured the behavioral effects of SNC80 in β -24 arrestin 2 KO mice, at a dose known to produce anxiolytic-like effects in wild-type (WT) 25 mice (van Rijn et al., 2010). As expected, systemic administration of SNC80 (20 mg/kg, s.c.)

1 significantly increased the time WT mice spent in the open arm (*elevated plus maze test:* Fig. 2 1d; two-way ANOVA, Drug effect: $F_{1, 68}$ = 8.781, p=0.004) and the light chamber (*Dark-light* 3 *box test:* Fig. 1e; Drug effect: $F_{1,59} = 4.978$, p=0.03). As we predicted, the anxiolytic effects 4 of SNC80 were attenuated in β -arrestin 2 KO mice (*Elevated plus maze test:* Fig. 1d; 5 Genotype effect: $F_{1, 68} = 3.15$, p=0.08; Dark-light box test: Fig. 1e; Genotype effect: $F_{1, 59} =$ 6 1.039, p=0.312). Although the total movement in the elevated plus maze was slightly lower 7 in β -arrestin 2 KO mice than WT mice, no drug effects were observed in both genotypes 8 (elevated plus maze test: Fig. 1f; two-way ANOVA, Drug vs. Genotype effect: $F_{1, 68} = 0.339$, 9 p=0.56; Genotype effect: F_{1, 68} = 20.7, p<0.0001; Drug effect: F_{1, 68} = 0.796, p=0.38). 10 Likewise, no statistical difference in total transition was observed in the dark light transition 11 box test (*dark-light box test:* Fig. 1g; two-way ANOVA, Drug vs. Genotype effect: $F_{1, 57} =$ 1.754, p=0.19; Genotype effect: $F_{1,57} = 0.1222$, p<0.0001; Drug effect: $F_{1,57} = 0.037$, p=0.85); 12 13 however, as previously described, SNC80 produced hyperlocomotive behavior in mice 14 ((Chiang et al., 2016), Fig. S1). 15 16 The β -arrestin recruiting δ OR agonist SNC80 strongly activates ERK1/2 *in vitro* and *in* 17 vivo 18 Activation of κOR has been associated with β -arrestin 2-mediated p38 phosphorylation 19 (Bruchas et al., 2006). To determine if δOR agonism similarly stimulates mitogen-activated 20 protein kinases (MAPKs), we measured p38, JNK, and ERK1/2 activation in Chinese 21 Hamster Ovarian cells stably expressing δOR and β -arrestin 2 (CHO- δOR - $\beta Arr2$) following 22 stimulation with 10 µM SNC80, a concentration that will fully activate G-protein signaling 23 and induce β -arrestin 2 recruitment (Robins et al., 2018b). We found that SNC80 led to a 24 rapid increase in ERK1/2 phosphorylation within 3 minutes in CHO- δ OR- β Arr2 cells, which

25 lasted until 60 minutes, in agreement with previous δ OR-mediated ERK activation in CHO

1	cells (Rozenfeld and Devi, 2007). We did not observe strong activation of p38 and JNK by
2	SNC80 (Fig. 2a). The δOR mediated ERK1/2 signaling in these cells were not an artifact of
3	the recombinant overexpression of δOR and β -arrestin 2 in the CHO cells as we observed a
4	similar profile for ERK1/2 activation in NG108-15 neuroblastoma cells endogenously
5	expressing δOR and β -arrestin (Cen et al., 2001; Eisinger et al., 2002; Klee et al., 1982) (Fig.
6	2b ; one-way ANOVA, $F_{4,30}$ =6.958, <i>p</i> <0.0001). We similarly found ERK1/2 activation in
7	several mouse brain regions, known to express δORs , including the dorsal hippocampus, the
8	amygdala and the striatum (Chu Sin Chung et al., 2015; Erbs et al., 2015) (Fig. 2c-e). The
9	SNC80-induced ERK1/2 activation in these regions was confirmed and quantified by the
10	Western blot analysis of flash-frozen tissue punches upon collection (Fig. 2f). Here, we
11	observed that SNC80 (20 mg/kg, i.p.) significantly increased ERK1/2 phosphorylation at the
12	10-minute time-point in all tested brain regions except for the ventral hippocampus of WT
13	mice (Fig. 2g-k; see Table S1 for one-way ANOVA and post-hoc multiple comparison), and
14	these activations returned to basal levels 30 minutes after the SNC80 administration.
15	
16	β -arrestin 2 is required to activate ERK1/2 signaling in the limbic structures of the
17	brain
18	To determine if β -arrestin 2 is responsible for the ERK1/2 activation in the tested brain
19	regions (Fig. 2g-k), we injected 20 mg/kg of SNC80 in the β -arrestin 2 KO mice (Fig. 3a)
20	and measured levels of ERK1/2 activation in the five brain regions tested in Figure 2. While,

SNC80 still strongly activated ERK1/2 in the striatum and the nucleus accumbens of the β arrestin 2 KO mice (**Fig. 3b-c**; see **Table S1** for one-way ANOVA and post-hoc multiple comparison), we did not observe significant SNC80-induced ERK1/2 activation in the amygdala, the ventral hippocampus and the dorsal hippocampus of these KO mice (**Fig. 3d-f**; see **Table S1** for one-way ANOVA and post-hoc multiple comparison).

1

2 ERK1/2 signaling plays a key role in the SNC80-mediated anxiolytic-like effects

3 We next assessed if the anxiolytic effects of SNC80 were dependent on ERK1/2 activation. 4 We administered wild-type mice with SL327, a MEK1/2 inhibitor that indirectly prevents 5 ERK1/2 activation, (Fig. 4a) (Tohgo et al., 2002). We found that SL327 (50 mg/kg, s.c.) 6 ablated the anxiolytic-like effects of SNC80 (20 mg/kg, i.p.) in WT mice (Fig. 4b, one-way 7 ANOVA, $F_{3,34}=12.35$, p<0.0001). Thus, SNC80 anxiolytic-like behavior relied on the 8 presence of β -arrestin 2 (Fig. 1d,e) and MEK/ERK1/2 activation (Fig. 2g-k). The 9 hippocampus is a brain region associated with anxiety-like behavior in the elevated plus maze 10 (File et al., 2000) 10837844 and δ OR-agonism in the dorsal hippocampus, as well as the 11 amygdala reduces anxiety-like behavior in the open field test (Saitoh et al., 2018; Solati et al., 12 2010). These published findings agree with our observation of SNC80-induced β -arrestin 2-13 dependent ERK1/2 activity specifically in these two brain regions (Fig. 3d,e). Therefore, if 14 the β -arrestin-mediated ERK1/2 signaling in these two regions was critical for the anxiolytic-15 like effects of SNC80, we would expect ERK1/2 activity to be abolished in these regions in 16 the mice co-treated with SNC80 and SL327. Indeed, we found that SL327 effectively 17 decreased SNC80-induced ERK1/2 activity in the dorsal hippocampus and the amygdala (Fig. 18 **4c,d**, see **Table S2** for detailed statistics).

19

Fear-potentiated startle behavior is correlated with ERK1/2 activity but is not mediated by β-arrestin 2

Besides reducing anxiety-like behavior, δOR activation can also alleviate conditioned fearrelated behavior (Saitoh et al., 2004; Sugiyama et al., 2019). Based on our results and previous studies, we hypothesized that SNC80 may similarly reduce fear-related behavior through a mechanism that involves β -arrestin 2. To measure conditioned fear, we utilized a

1 mouse behavior paradigm of fear-potentiated startle (FPS) (Fig. 5a). In WT mice (Fig. 5b), 2 we noted that SNC80 (20 mg/kg, i.p.) significantly reduced startle responses to the 3 unconditioned 'noise' cue as well as to the conditioned 'light+noise' cue (Fig. 5c; two-way 4 ANOVA, stimuli x drug effects: $F_{2,120}=20.42$, p<0.0001, stimuli effects: $F_{2,120} = 92.8$, 5 p < 0.0001, drug effects: F_{1,120}= 63.99, p < 0.0001), resulting in a significant reduction in % 6 FPS response (Fig. 5d; unpaired t-test, p=0.0085). To our surprise, we found that SNC80 was 7 equally effective in reducing % FPS responses in β -arrestin 2 KO mice (Fig. 5e-f; two-way) 8 ANOVA, stimuli x drug effects: $F_{2,42}=20.22$, p<0.0001, stimuli effects: $F_{2,42} = 51.52$, 9 p < 0.0001, drug effects: F_{1.42}= 40.4, p < 0.0001; noise: p = 0.01, light+noise: p < 0.0001 after 10 Bonferroni's multiple comparison; Fig. 5g; unpaired t-test, p=0.0003; Fig. 5d,g; comparison 11 between WT and β -arrestin 2 KO via two-way ANOVA, Genotype x Drug effect: F_{1,53}=1.306, p=2.583; Genotype effect: F_{1,53}=5.055, p=0.029; Drug effect: F_{1,53}=18.98, p<0.0001). While 12 13 SNC80 is a very efficacious recruiter of β -arrestin, it still also fully activates Gi protein 14 signaling (Chiang et al., 2016; Robins et al., 2018b). Thus, we next hypothesized that the 15 observed fear-reducing effects of SNC80 could be mediated through G_i protein signaling. To 16 address this hypothesis, we utilized a δOR selective agonist, TAN67, which is a poor 17 recruiter of β -arrestin (Fig. 5f), and considered G_i protein-biased (Chiang et al., 2016; Robins 18 et al., 2018b). However, when we administered TAN67 (25 mg/kg, i.p.) to our WT mice (Fig. 19 **5h**), we found that TAN67 did not significantly change startle to the noise or to the 20 light+noise stimuli (Fig. 5i; two-way ANOVA, stimuli x drug effects: F2,42=0.725, p=0.491, 21 stimuli effects: F2,42 = 25.06, p<0.0001, drug effects: F1,42 = 0.275, p=0.603), but it did 22 produce a significant increase in %FPS (Fig. 5j; unpaired t-test, p < 0.0001). The lack of a 23 direct effect of TAN67 on noise-alone startle is in agreement with our previous finding that 24 TAN67 did not change basal anxiety-like behavior in the elevated plus maze and dark-light 25 transition test (van Rijn et al., 2010). Interestingly, our Western blot analysis of ERK1/2

activities in WT mice revealed that this G_i protein-biased agonist, TAN67, decreased ERK1/2
phosphorylation in the dorsal striatum, the nucleus accumbens, the dorsal hippocampus and
the amygdala (Fig. 6a-d). In the ventral hippocampus, TAN67 did not alter ERK1/2 activity
(Fig. 6e), which was similar to the lack of ERK1/2 modulation by SNC80 in this region (Fig.
2m) and may be indicative of low δOR expression in the ventral region as previously
described (Mansour et al., 1987).

7

8 Potential roles for ERK1/2 and β-arrestin 1 in the modulation of conditioned-fear 9 behavior

10 Our results suggest that SNC80 reduces conditioned fear through a mechanism that does not 11 involve β -arrestin 2 or G protein signaling. Therefore, we next hypothesized that the effect 12 may be mediated by β -arrestin 1 instead. However, SNC80 is known to induce severe 13 seizures in β -arrestin 1 KO mice (Vicente-Sanchez et al., 2018), preventing us from testing 14 the FPS response of SNC80 in this strain. Instead, we measured SNC80-induced ERK1/2 15 phosphorylation in the β -arrestin 1 KO mice. In comparison to WT mice (Fig. 2g-k), genetic 16 knockout of β-arrestin 1 prevented SNC80-mediated ERK1/2 phosphorylation in the dorsal 17 striatum and nucleus accumbens (Fig. 6f-g; see Table S3 for one-way ANOVA and post-hoc 18 multiple comparison). In the amygdala and dorsal hippocampus of β -arrestin 1 KO mice, 19 SNC80 did increase ERK1/2 phosphorylation (Fig. 6h-i), but in contrast to the response 20 observed in WT mice, the activation was sustained for at least 30 minutes. Additionally, we 21 observed the same trend in the ventral hippocampus (Fig. 6j), a region where we had 22 observed no δOR agonist-mediated modulation of ERK1/2 in WT mice (Fig. 2k and Fig. 6e). 23 Thus, we hypothesized that the increased ERK1/2 in these regions is most likely a result of 24 seizure activity and not necessarily a result of δ OR-mediated effects.

1

2

Discussion

3 Here, we investigated the hypothesis that β -arrestin can modulate anxiety- and conditioned 4 fear-related behavior via downstream MAPK activation. By utilizing G protein- and β -5 arrestin-biased δOR agonists together with β -arrestin-isoform selective knockout mice, we 6 discovered that G protein, β -arrestin 1, and β -arrestin 2 uniquely modulated ERK1/2 activity 7 resulting in differential outcomes in mouse models of anxiety/fear-related behavior. Our 8 results suggest that the reduction in anxiety-like behavior by SNC80 required the presence of 9 β -arrestin 2 as well as activation of ERK1/2. Distinctly in the dorsal hippocampus, we found 10 that ERK1/2 activation was β -arrestin 2-dependent (Fig. 7a). Notably, G protein-biased 11 signaling by TAN67 reduced ERK1/2 phosphorylation and was correlated with increased 12 FPS (Fig. 7b). We found that SNC80-induced ERK1/2 activation in the nucleus accumbens 13 and the dorsal striatum required β -arrestin 1, which may be part of the mechanism for SNC80 14 to decrease FPS (Fig. 7c).

15 Differential roles for β -arrestin isoforms in neuropsychiatric behavior. The β -arrestin 16 proteins were discovered in quick succession (Attramadal et al., 1992; Lohse et al., 1990). 17 Surprisingly, despite the availability of genetic KO mice for each isoform (Bohn et al., 1999; 18 Conner et al., 1997). Studies investigating β -arrestin in the CNS have largely focused on β -19 arrestin 2 and have generally neglected β -arrestin 1 (Latapy and Beaulieu, 2013; Whalen et 20 al., 2011). A potential reason for the preference of studying β -arrestin 2 may be that when the 21 β -arrestin 2 knockout mice were generated their first utilization was to highlight the proteins' 22 involvement with the CNS-mediated adverse effects of µ-opioid receptor agonism (Bohn et 23 al., 2000; Raehal et al., 2005). Researchers have only recently begun to utilize β -arrestin 1 24 KO mice to study various neurological disorders. In 2016, Pradhan et al. found that different 25 δOR agonists either preferentially recruited β -arrestin 1 leading to δOR degradation or

recruited β-arrestin 2 causing δOR resensitization (Pradhan et al., 2016). A study in 2017
 found that amphetamine-induced hyperlocomotion was amplified in β-arrestin 1 KO mice,
 but attenuated in β-arrestin 2 KO mice (Zurkovsky et al., 2017), further emphasizing the
 importance of studying both β-arrestin isoforms.

5 As mentioned, our study further identified that SNC80-induced anxiolytic-like effects 6 were β -arrestin 2-dependent. However, β -arrestin 2 KO mice still exhibited the fear-reducing 7 effect of SNC80, which could suggest a potential role for β -arrestin 1 in the modulation of 8 fear-related behavior. Particularly, we also noted that β-arrestin 1 KO abolished SNC80-9 induced ERK1/2 activation in the striatum and nucleus accumbens. Our findings were in line 10 with the extensive *in-situ* hybridization studies on differential β -arrestin isoform levels in 11 neonatal and postnatal rats (Gurevich et al., 2002, 2004) and studies showing relatively high 12 β -arrestin 1 and low β -arrestin 2 expressions in the striatal regions (Attramadal et al., 1992; 13 Bjork et al., 2008; Gurevich et al., 2002). In contrast, SNC80-induced ERK1/2 activation in 14 the dorsal hippocampus and amygdala was β -arrestin 2-dependent, which agreed with reports 15 of stronger expression of this isoform in those areas (Attramadal et al., 1992; Bjork et al., 16 2008). Unfortunately, we were limited in our ability to assess whether SNC80-induced 17 reduction in FPS would be attenuated in β -arrestin 1 KO mice, as SNC80 produces severe 18 seizures in these mice (Vicente-Sanchez et al., 2018), a phenomenon we have also observed 19 ourselves and found to be accompanied by strong and persistent ERK1/2 activation in the 20 dorsal hippocampus. Further investigation of the roles of β -arrestin 1 in neuropsychiatric 21 behavior may be feasible using a conditional knockout approach; currently conditional β -22 arrestin 2 knockout mice already exist (Huang et al., 2018), but conditional β -arrestin 1 23 knockout mice have not yet been reported.

24 A unique role for G_i protein signaling and ERK1/2 signaling in conditioned fear-25 related behavior. In contrast to the β -arrestin-mediated activation of ERK1/2, we found that

1 selectively activating the G protein pathway of the δOR using TAN67, a known weak 2 recruiter of β -arrestin 1 and 2 (Chiang et al., 2016) (Fig. S2) decreased ERK1/2 activation, 3 including in the striatum and the amygdala, and was associated with increased FPS. This 4 result is in agreement with the observation and that blocking $G_{i/o}$ protein signaling using 5 pertussis toxin in the basolateral amygdala reduced FPS (Melia et al., 1992) and parallels 6 finding that TAN67 did not reduce unconditioned anxiety-like behavior in naïve mice (van 7 Rijn et al., 2010). Additionally, a study in ovariectomized mice found that estradiol benzoate, 8 an anxiogenic estradiol prodrug (Morgan and Pfaff, 2002), decreased ERK in the 9 hippocampus (Anchan et al., 2014), which supports our finding that decreased ERK1/2 is 10 correlated with increased fear. It is noteworthy that both G_i protein and β -arrestin can activate 11 ERK1/2 albeit via different mechanisms (Goldsmith and Dhanasekaran, 2007; Gutkind, 12 2000). One explanation for our observation is that TAN67 competes with the endogenous 13 δOR agonist Leu-enkephalin, which is a much more efficacious recruiter of β -arrestin 14 (Chiang et al., 2016) (Fig. S3). Importantly, based on observations of enhanced anxiety-like 15 behavior in preproenkephalin KO mice, Leu-enkephalin has anxiolytic-like effects by itself 16 (Kung et al., 2010; Ragnauth et al., 2001), which is in line with reports that the δOR 17 antagonist, naltrindole, is anxiogenic (Narita et al., 2006). As a weak β -arrestin recruiter, 18 TAN67 would attenuate any baseline Leu-enkephalin-induced β-arrestin-mediated ERK 19 activity (Fig. S3). In contrast, because SNC80 is a stronger β -arrestin recruiter than Leu-20 enkephalin, it will elevate basal ERK1/2 activity produced by endogenous opioids. This 21 hypothesis would also explain why SNC80-induced ERK1/2 activation is quite variable and 22 produces on average only a two-fold increase.

 β -arrestin serves as a scaffold for a range of kinases and effectors. In our study, we found that δOR agonism strongly activates ERK1/2 compared to the other tested MAPKs, p38 and JNK, and that the ERK1/2 activity induced by SNC80 was negatively correlated with

1 FPS. Other GPCRs, besides the δOR , may also require β -arrestin-dependent ERK1/2 2 signaling for modulation of fear. Specifically, in the infralimbic prefrontal cortex, β -3 adrenergic receptor activation can promote the extinction of contextual fear memory (Do-4 Monte et al., 2010). In a recent study, it was shown that in this same brain region β -arrestin 2-5 dependent ERK1/2 activation was required for β -adrenergic receptors agonists to stimulate 6 extinction learning of cocaine-induced reward memories (Huang et al., 2018). β-arrestin 2-7 mediated signaling in the CNS is not exclusive to ERK1/2 signaling; following KOR 8 activation, β -arrestin 2 can scaffold with p38 as part of a potential mechanism for the 9 aversive effects of κOR agonists (Bruchas et al., 2007). A β-arrestin 2 scaffold of AKT, 10 GSK3 β and PP2A has been proposed as a mechanism for stabilizing mood (O'Brien et al., 11 2011), highlighting that β -arrestin signaling is also not limited to MAPKs. In fact, because β -12 arrestin 1, in contrast to β -arrestin 2, contains a nuclear translocation sequence (Hoeppner et 13 al., 2012), this enables it to enter the nucleus and regulate gene transcription (Kang et al., 14 2005; Shi et al., 2007). While in this study we report δORs require β -arrestin-dependent ERK 15 signaling for reduction in anxiety-like behavior, it is certainly possible that other GPCRs may 16 engage different intracellular signaling pathways following β -arrestin recruitment.

17 Fear- and anxiety-like behaviors rely on shared but distinct neural circuits. In our 18 study, we observed that β -arrestin 2-dependent ERK1/2 activity in the dorsal hippocampus 19 was associated with reduced anxiety-like behavior. Generally, CA1 regions of the ventral 20 hippocampus are associated with responding to contextually-conditioned anxiogenic stimuli 21 than dorsal CA1 regions (Fanselow and Dong, 2010; Jimenez et al., 2018), whereas the 22 dorsal hippocampus is involved with cognitive functions, including exploration, navigation 23 and memory (Kheirbek et al., 2013). Still, our finding that δOR signaling in the dorsal 24 hippocampus is connected to the anxiolytic-like effects of SNC80, agrees with a study 25 showing that intra-dorsal CA1 injection of the δOR antagonist naltrindole is anxiogenic

1 (Solati et al., 2010). Additionally, the anxiolytic-like effects of SNC80 may also involve β -2 arrestin 2-dependent ERK1/2 signaling in the amygdala, a region more commonly associated 3 innate anxiety-like behavior (Felix-Ortiz et al., 2013; Tye et al., 2011). The basolateral 4 amygdala (BLA) also plays an important role in fear conditioning (Janak and Tye, 2015), 5 including FPS (Terburg et al., 2018). The BLA receives dopaminergic inputs from the ventral 6 tegmental area and projects to the nucleus accumbens. It has been proposed that 7 dopaminergic signaling in the BLA is important for cue-dependent fear-conditioning, such as 8 FPS (Fadok et al., 2009) and that the BLA to nucleus accumbens projection is critical for 9 consolidation of memories associated with aversive effects such as foot shock (Fadok et al., 10 2010; LaLumiere et al., 2005).

11 Our finding that ERK1/2 activation in the striatal regions was ablated in β -arrestin 1 12 KO mice points to a role for striatal β -arrestin 1-mediated ERK1/2 signaling in the 13 modulation of the expression of conditioned fear-related behavior. Processing and executing 14 emotional behaviors in tasks such as the elevated plus maze and FPS tests engages multiple 15 overlapping, yet distinct, brain regions and circuits involved in memory retrieval, locomotion, 16 decision making, reward, and mood (Janak and Tye, 2015). Further studies with circuit-based 17 approaches are necessary to assess the role of biased signaling pathways in the acquisition 18 and expression of conditioned fear-related behavior.

Beneficial roles of β-arrestin signaling. For the longest time, β-arrestin 2 has been
associated solely with adverse effects of opioid activation, including tolerance, constipation,
respiratory depression, aversion and alcohol use (Raehal and Bohn, 2011; Raehal et al., 2005;
van Rijn et al., 2010). These studies fueled a drive to develop G protein-biased opioids to
treat pain and other disorders with an improved therapeutic window (Manglik et al., 2016;
Mores et al., 2019). Yet, recently a number of studies have started to push back against this
narrative (Austin Zamarripa et al., 2018; Hill et al., 2018; Kliewer et al., 2019). Clearly, β-

1 arrestin signaling is not inherently negative as the therapeutic effects of lithium and 2 fluoxetine seem to depend on β -arrestin 2 (David et al., 2009). The increased propensity for 3 β -arrestin 1 KO mice to experience SNC80-induced seizure points to a potential beneficial 4 role for this isoform in maintaining seizure threshold, which could be of use in the treatment 5 of epilepsy. In this study, we provide additional insights regarding potential therapeutic 6 benefits of β -arrestin signaling in reducing anxiety-like behavior. Providing adequate relief of 7 chronic pain is not trivial, partly because it is often associated with negative affect (Corder et 8 al., 2019; Massaly et al., 2019) including anxiety, which may exacerbate pain (al Absi and 9 Rokke, 1991). δOR agonists have been proposed as potential treatment for chronic pain 10 disorders (Pradhan et al., 2011), partly because they have the ability to not only provide 11 analgesia, but also treat comorbid anxiety and depression (Perrine et al., 2006; Saitoh et al., 12 2004; van Rijn et al., 2010). However, our results would argue that developing G protein-13 biased δOR agonists may produce drugs that are suboptimal for the treatment of complex 14 chronic pain; our findings suggest such a drug would not alleviate co-morbid fear and anxiety, 15 but potentially even worsen these symptoms. Thus, our study results argue in favor of a 16 reassessment of drug development efforts that seek solely to identify G protein-biased drugs. 17 Instead, we propose that efforts should be directed towards the development of drugs with 18 finely tuned bias and, if possible, towards development of molecules that are biased against a 19 single β -arrestin isoform rather than both isoforms.

Conclusion. Overall, our results begin to reveal the complex- and context-specific
nature of GPCR biased signaling in modulation of fear-related and anxiety-like behavior.
These results expand our current understanding of therapeutic effects of β-arrestin signaling
in mood disorders, which ultimately may aid development of more efficacious
pharmacological treatment options for these disorders.

25

1	Author Contributions
2	MJ.K.: formal analysis, investigation, writing - original draft, writing - review & editing,
3	visualization; T.C.: formal analysis, investigation, writing - review & editing; G.E.M.:
4	formal analysis, investigation, writing - review & editing; A.M.M. formal analysis,
5	investigation; A.M.G. formal analysis, investigation, writing - review & editing; J.A.C.:
6	formal analysis, writing - review & editing, supervision; R.M.vR.: Conceptualization, formal
7	analysis, investigation, writing - original draft, writing - review & editing, visualization,
8	supervision, project administration, funding acquisition
9	
10	
11	Acknowledgements
12	This work was funded by a NARSAD Young Investigator Award from the Brain and
13	Behavior Research Foundation (#23603 to RMvR) and the National Institute on Alcohol
14	Abuse and Alcoholism (AA025368, AA026949, AA026675) and Drug Abuse (DA045897).
15	We also appreciate Dr. Marcus M. Weera for technical assistance with the fear-conditioning
16	experiments. Included diagrams were created with BioRender.
17	
18	Declaration of Interests
19	The authors declare that the research was conducted in the absence of any commercial or
20	financial relationships that could be construed as a potential conflict of interest.
	manetal relationships that could be construct as a potential connect of interest.
21	
22	Figure legends
23	Figure 1. Beneficial role for β-arrestin 2 in reducing anxiety-like behavior (a) Chemical
24	similarity between AZD2327, a δOR agonist used in phase II clinical trials for anxious

1 major depressive disorder and SNC80. (b) Scheme highlighting that SNC80 is δOR 2 selective agonist, that activates Gi proteins but also strongly recruits β -arrestin 2. (c) 3 Schematic diagram of the elevated plus maze test and dark-light box test. (d) The β -arrestinbiased δOR agonist, SNC80 (20 mg/kg, s.c.), significantly increased percentage of time spent 4 5 in open arms in WT mice (n=15). but not β -arrestin 2 KO mice (n=21). (e) SNC80 increased 6 percentage of time spent in light box in WT mice (control: n=12, SNC80: n=11), but not in β -7 arrestin 2 KO mice (n=20). (f) The total time of movements were equal between drug 8 treatments. (g) No statistical significance was observed in the total transitions between light 9 and dark chambers. (Significance was calculated by two-way ANOVA followed by a Sidak's 10 multiple comparison; *p < 0.05; all values are shown as individual data points \pm S.E.M.).

11

12 Figure 2. The anxiolytic agonist SNC80 activates ERK1/2 in vitro and in the limbic and 13 striatal regions of the brain (a) 10 uM SNC80 strongly increased ERK1/2 phosphorylation, 14 compared to p38 and JNK, in CHO cells stably expressing δOR and β -arrestin 2. A 15 representative Western blot image is presented to the right. (b) SNC80 increased ERK1/216 phosphorylation in a time-dependent manner, in NG-108-15 cells endogenously expressing 17 δOR . A representative Western blot image is shown on the right. Representative 18 immunoflouresence staining images of the limbic regions (c) and striatal regions (d) from 19 mice 10 minute post administration of saline or SNC80 (20 mg./kg i.p.; Green: ERK; Red: 20 pERK; Blue: DAPI; Image was stitched at 10x magnification and the scale is provided in the 21 image). (e) 20x magnification images of the hippocampal/amgdalar and striatal slices (The 22 corresponding location is marked in white squre in 10x images). (f) Representative images of 23 brain sections with micropunctures of five specified brain regions for the Western blot 24 analysis. (g-k) Activation of ERK1/2 protein activity following systemic administration of 25 SNC80 in five wild-type mice brain regions. Representative Western blot images are depicted

1	below the respective bar graph (For (a), significance was measured by two-way ANOVA
2	followed by a Dunnett's multiple comparison. For (c, i-m), significance was analyzed by one-
3	way ANOVA followed by a Tukey's multiple comparison; * $p < 0.05$, ** $p < 0.01$, **** $p < 0.01$
4	0.0001; all values are shown as individual data points \pm S.E.M.).
5	
6	Figure 3. ERK1/2 activation in the amygdala and the dorsal hippocampus are β -arrestin
7	2 dependent (a) Schematic diagram of the cellular context in β -arrestin 2 genetic KO mice.
8	SNC80 (20 mg/kg, i.p.) induced ERK1/2 activation in the dorsal striatum (b) and nucleus
9	accumbens (c). β -arrestin 2 KO ablated the SNC80-induced ERK1/2 activation in the dorsal
10	hippocampus (d) and the amygdala (e) with no effects in the ventral hippocampus. (f)
11	Representative Western blot images are shown tothe right of the related bar graph.
12	(Significance was analyzed by one-way ANOVA followed by a Tukey's multiple

13 comparison; p < 0.05, p < 0.01; all values are shown as individual data points \pm S.E.M.).

14

15 Figure 4. ERK1/2 is required for the anxiolytic-like effects induced by SNC80 (a) A 16 schematic diagram of SL327 induced inhibition of SNC80 mediated ERK1/2 signaling. (b) 17 SL327 (50 mg/kg, s.c.), attenuated the anxiolytic-like effects of SNC80 (20 mg/kg i.p.) in 18 WT mice (control: n=8, SNC80: n=12, SNC+SL: n=12, SL327: n=12). (c-d) SL327 19 significantly inhibited SNC80-induced ERK1/2 phosphorylation in the dorsal hippocampus 20 and the amygdala (Significance was calculated by one-way ANOVA followed by a Sidak's 21 or Tukey's multiple comparison; p<0.05, p<0.01, p<0.001, p<0.001, p<0.001, p<0.05; 22 all values are shown as individual data points ± S.E.M.; SNC+SL means SNC80+SL327 and 23 SL means SL327).

1 Figure 5. Unique modulation of fear-potentiated startle (FPS) by a β -arrestin-biased 2 and G protein-biased δOR agonist (a) Schematic representation of the three-day 3 experimental paradigm of the fear potentiated startle test; drugs were administered prior to 4 the tests on the third day (See Figure S4 for Day 1 acoustic startle test). (b-d) SNC80 (n=21) 5 reduced raw startle amplitudes to noise or light+noise and % FPS during the FPS test in WT 6 mice. (e-g) SNC80 also reduced raw startle amplitudes to noise or light+noise and % FPS in 7 β-arrestin 2 KO mice (n=8). (h-j) Yet, G protein-biased agonist, TAN67, increased % FPS in 8 WT mice (n=8) (Significance was measured by two-way ANOVA followed by a Tukey's multiple comparison or unpaired t-test; p < 0.05, p < 0.01, p < 0.001, p < 0.001, p < 0.001; 9 10 all values are shown as individual data points \pm S.E.M.).

11

12 Figure 6. Differential roles for G protein and β -arrestin 1 in δ OR agonist-induced 13 ERK1/2 activation (a-e) The G protein-biased δOR agonist TAN67 (25 mg/kg, i.p.), 14 decreased the basal ERK1/2 activity in all tested brain regions of wild-type mice. 15 Representative Western blot images are depicted next to each related bar graph. (f-j). 16 Systemic administration of SNC80 (20 mg/kg, i.p.) did not activate ERK1/2 in the striatal 17 regions of β -arrestin 1 KO mice but resulted in persistent ERK1/2 activation in the dorsal and 18 ventral hippocampus and amygdala (Significance was analyzed by one-way ANOVA 19 followed by a Tukey's multiple comparison; p < 0.05, p < 0.01; all values are shown as 20 individual data points \pm S.E.M.).

21

Figure 7. Graphical summary δOR agonists differentially induce ERK activation in a β arrestin isoform specific manner to modulate anxiety- and conditioned fear-related behaviors. SNC80 induced β -arrestin 2-mediated ERK1/2 activation (*Cellular Makeup*) in the hippocampus and amygdala (*Localization*) decreased anxiety-like behavior (**a**), whereas an

increase in conditioned fear-related behavior (*Behavior*) by TAN67 can be linked to
 decreased ERK1/2 activity in all tested brain regions except for the ventral hippocampus (b).
 Decreased FPS could not be correlated with G protein or β-arrestin 2 signaling, but may
 involve β-arrestin -1 dependent ERK1/2 signaling in the dorsal striatum and nucleus
 accumbens (c).
 9

	4	

STAR Methods

2	Animals Wild-type (WT) C57BL/6 male mice were purchased from Envigo (Indianapolis,
3	IN), and β -arrestin 1 or 2 global knockout (KO) mice were bred in our facility (Chiang et al.,
4	2016; Robins et al., 2018a). Adult mice (8-10 weeks, $24 \pm 2g$) were group housed (3-5 mice)
5	in a single ventilated Plexiglas cage. Mice were maintained at ambient temperature (21°C) in
6	an animal housing facility approved by the Association for Assessment and Accreditation of
7	Laboratory Animal Care and animals were kept on a reversed 12-hour dark-light cycle (lights
8	off at 10:00, lights on at 22:00). Food and water were provided ad libitum. Purchased mice
9	were acclimated for one week prior to the experiments. All animal protocols (#1305000864
10	by RMvR) were preapproved by Purdue Animal Care and Use Committee and were in
11	accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory
12	Animals.
13	Drug preparation and administration SNC80 (#076410, Tocris, Thermo Fisher Scientific,
14	Waltham, MA) was diluted in slightly acidic saline pH5-6. TAN67 (#092110, Tocris,

15 Thermo Fisher Scientific) was diluted in saline, and SL327 (#19691, Tocris, Thermo Fisher 16 Scientific) was diluted in 5% DMSO, 10% Cremophore (Millipore Sigma, Burlington, MA) 17 and 85% saline. 20 mg/kg SNC80 was subcutaneously administered 30 minutes prior to the 18 tests in Fig. 1d-g, Fig. 4b and Fig. S1, and 50 mg/kg SL327 was subcutaneously 19 administered 60 minutes prior to the administration of SNC80 for Fig. 4. For Fig. 2-6 and 20 Fig. S4, either 20 mg/kg SNC80 or 25 mg/kg TAN67 was intraperitoneally administered at 21 the indicated timepoint prior to the testing. The dose of SNC80 and TAN67 was determined 22 based on our previous study (van Rijn et al., 2010) and our preliminary studies (data not 23 shown). Separate batches of mice with no prior history of drug injection were used for the 24 brain collection and behavioral tests to test earlier time-points of ERK1/2 signaling (such as 25 10 minutes).

Elevated-plus maze test The elevated-plus maze test was performed as previously described
 (van Rijn et al., 2010). Mice were allowed to explore the maze for 5 minutes, and arm entries
 and time spent in each arm were recorded with a camera positioned above the maze.

4 **Dark-light transition box test** The test was performed based on previously established 5 protocols (Robins et al., 2018a; van Rijn et al., 2010) Testing was conducted without a 6 habituation session to the boxes and a 1/2 area dark insert was placed in the locomotor boxes, 7 leaving the remaining 1/2 of the area lit as described previously (Bourin and Hascoet, 8 2003)(Bourin and Hascoet, 2003). Two LED lights were inserted above the light portion of 9 the testing chamber where the lux of the light region ranged from 390-540 lumens and dark 10 chamber lux ranged from 0-12 lumens. For testing, animals were placed in the light portion 11 of the chamber and testing began upon animal entry. Time spent in the dark and light 12 chambers as well as their locomotor activity was recorded for 5 minutes with a photobeam-13 based tracking system.

14 Fear potentiated startle (FPS) test Startle reflexes of mice were recorded in the startle 15 reflex chambers (25.8 x 25 x 26.5 cm) using the Hamilton Kinder Startle Monitor system 16 (Kinder Scientific, Poway, CA). Mice groups were counterbalanced, such that no significant 17 differences between startle reflexes were observed between groups (Fig. S4). On the 18 conditioning day, all subjects were conditioned with 40 conditioning trials by a fixed 2 19 minute inter-trial interval (ITI), and FPS responses were tested on the following day. The fear 20 conditioning and FPS parameters were based on a previously established protocol (Barrenha 21 and Chester, 2007).

Preparation of tissue homogenates After drug injections, mice were euthanized by carbon dioxide asphyxiation and rapidly decapitated. Based on our previous studies, we have particularly chosen carbon dioxide asphyxiation over other euthanasia methods that may potentially increase basal ERK1/2 activity in the brain (Ko et al., 2019). The collected brains

1 were first sliced as coronal sections (1.5-2.0 mm) with a brain matrix (#RBMS-205C, Kent 2 scientific, Torrington, CT), and then flash-frozen in dry-ice-chilled 2-methylbutane (-40 °C) 3 (#03551-4, Fisher Scientific). Regions of interest were collected from these slices using a 1 4 mm biopsy micropunch (#15110-10, Miltex, Plainsboro, NJ) as follows: dorsal striatum and 5 nucleus accumbens (A/P: +0.5 mm to +1.5 mm), dorsal hippocampus and amygdala (A/P: -1 6 mm to -2 mm), and ventral hippocampus (A/P: -2 mm to -4 mm) (Paxinos and Franklin, 7 2004). The punches targeted a specific region and produced enough tissue to run several blots. 8 However, it is noteworthy that the extracted tissue may contain small amounts of tissue from 9 neighboring regions. For example, while the punches for the amygdala primarily consisted of 10 the BLA, the tissue will also have included a small portion of the central amygdala. Collected 11 tissues were further homogenized with a tissue grinder (#357535 & 357537, DWK Life Sciences, Millville, NJ) in RIPA buffer mixed HaltTM Protease and Phosphatase Inhibitor 12 13 Cocktail (#1861280, Thermo Fisher Scientific). Samples were further prepared based on 14 previously established protocols (Ko et al., 2019). Data depicted in Fig. 2i-m also includes 15 the data collected for SNC80 at the 0 min or 10 min time points in the experiment depicted in 16 Fig. 4c, dto represent the full range of observed SNC80 induced ERK1/2 activation in mice 17 tested in separate cohorts at different occasions.

18 **Cell culture** Chinese hamster ovarian CHO- δ OR- β Arr2 cells (DiscoverX, Fremont, CA) 19 U2OS-δOR-βArr1 (DiscoverX), and NG-108-15 cells (HB-12317TM, ATCC®, Manassas, 20 VA) were cultured as recommended by the manufacturer and maintained at 37° C/5 % CO₂. Cells were seeded in a clear 6 well plate (CorningTM, Thermo Fisher Scientific) with 250,000 21 22 cells/2 mL/well. On the following day, all growth media was aspirated and changed into 1 23 mL serum-free Opti-MEM (#31985070, Gibco®, Thermo Fisher Scientific). The next day, 24 cells were challenged with 10 μ M drugs (SNC80) for a specific duration (0, 3, 6, 20, and 60 25 minutes). All drugs were diluted in Opti-MEM prior to administration. The media was

aspirated following the challenge and 100 μ L RIPA buffer was added to collect the samples on ice. Using cell scrapers (#353089, Thermo Fisher Scientific), all samples were dislodged from the 6 well plate, collected and stored at -30° C until usage. For the Western blot, the collected samples were quantified with the Bradford assay and samples were prepared with 4 x Laemmli and boiled at 95° C for 5 minutes. The CHO- δ OR- β Arr2 cells were also used to measure β -arrestin recruitment using the DiscoverX PathHunter Assay as previously described (Chiang et al., 2016).

8 **SDS-Page and Western blot** Samples (20 μ L containing 10 μ g protein) were loaded per 9 well of a NuPage 4-12 % Bis-Tris gradient gels (#NP0336BOX, Thermo Fisher Scientific), 10 and the SDS-Page gel was subsequently transferred to nitrocellulose membranes (#1620115, 11 BioRad) by the Western blot. Membranes were incubated following previously established 12 protocols (Ko et al., 2019). For reproducibility, detailed information regarding the antibodies 13 used in the study are listed in Table S4. Prepared samples were scanned using the LiCor 14 Odyssey® CLx Scanner (Li-Cor, Lincoln, NE). By utilizing the Li-Cor secondary antibodies, 15 we were able to detect the MAPK, pMAPK, and α -Tubulin on the same blot without the need 16 of stripping/reblotting. In the same membrane, each band was cut based on their size. For 17 instance, ERK1/2 and pERK1/2 bands were collected around 42/44 kDa and α -Tubulin band 18 was collected around 50 kDa in the same membrane. For statistical analysis, we normalized 19 the pMAPK/MAPK ratio to α -Tubulin in case drug treatment changed ERK1/2 levels.

Preparation of tissue for immunofluorescence To preserve the intact ERK1/2 activity in vivo for fluorescence microscopy, mice were transcardially perfused before isolation of brain tissue. Thirty minutes prior to transcardiac perfusion, mice were administered with 100/10 mg/kg Ketamine/Xylazine. Ten minutes prior to perfusion, 20 mg/kg SNC80 (i.p.) or a corresponding volume of saline was administered to the mice. Mice were then perfused with 30 mL of cold PBS and 4% paraformaldehyde (#100503-916, VWR, Radnor, PA) and were

1 immediately decapitated to collect the brains. The brains were fixated in 4% 2 paraformaldehyde overnight, dehydrated in 30% sucrose, and then embedded in Frozen 3 Section Compound (#3801480, Leica, Wetzlar, Germany). Frozen brains were sliced at a 4 width of 30 μ m using the Leica cryostat and permeabilized in 100% methanol at - 20 °C for 5 10 minutes. The slices were blocked in 5 % Normal goat serum (#S26-100ml, Millipore 6 Sigma) for an hour then stained with primary antibodies as listed in Table S4. For 7 immunofluorescence labeling, the sections were incubated in the secondary antibodies 8 according to the previously established protocol (Kim et al., 2018) and as listed in Table S4. 9 After the final washing, the nuclei of the sections were stained and the slices were mounted 10 on a glass slide with Vectashield® (#H-1200, Vector lab, Burlingame, CA). Images were 11 acquired with a Nikon confocal microscope and assembled in Adobe Photoshop CS6 (Adobe). 12 Statistical analysis The maximum amplitude of the startle response was measured from the 13 average of all responses for each trial type (12 noise-alone, 12 light+noise) of each mouse. 14 Fear-potentiated startle response was analyzed using raw (maximum) startle amplitudes and 15 proportional changes of each trial type (noise-alone, light+noise), which is shown as % FPS 16 in the graphs. The proportional change score (% FPS) was calculated as follows: (startle 17 response to light and noise – startle response to noise)/startle response to noise x 100. 18 Thus, %FPS is a sensitive measure that adjusts for individual and group differences (e.g., 19 possible non-specific effects of drug treatment) in startle response magnitude that may be 20 observed on noise-alone and light + noise trials (Walker and Davis, 2002).

All data are presented as individual data points (or means) \pm standard error of the mean (S.E.M.). Assays with one independent variable were analyzed for statistical significance using a one-way Analysis of Variance (ANOVA), whereas assays with two independent variables were analyzed using a two-way ANOVA. If a significant deviation of the mean was identified, an appropriate post-hoc analysis was performed as indicated.

1	Gaussian distribution of our datasets was assessed using the D'augostino and Pearson
2	analysis. We excluded one outlier in our wild-type cohort that received SNC80 and one that
3	received TAN-67 in the FPS assay based on the Grubbs' test ($\alpha = 0.05$). In the dark-light and
4	elevated plus maze tests we excluded subjects that were frozen/stationary for >95% of the
5	experimental time. All statistical analysis was conducted using GraphPad Prism 7 (GraphPad
6	Software, La Jolla, CA).
7	
8	
9	References
10	Akimova, E., Lanzenberger, R., and Kasper, S. (2009). The serotonin-1A receptor in anxiety
11	disorders. Biol Psychiatry 66, 627-635.
12	al Absi, M., and Rokke, P.D. (1991). Can anxiety help us tolerate pain? Pain 46, 43-51.
13	Allen, J.A., Yost, J.M., Setola, V., Chen, X., Sassano, M.F., Chen, M., Peterson, S., Yadav,
14	P.N., Huang, X.P., Feng, B., et al. (2011). Discovery of beta-arrestin-biased dopamine D2
15	ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc
16	Natl Acad Sci U S A 108, 18488-18493.
17	Anchan, D., Clark, S., Pollard, K., and Vasudevan, N. (2014). GPR30 activation decreases
18	anxiety in the open field test but not in the elevated plus maze test in female mice. Brain
19	Behav 4, 51-59.
20	Atkins, C.M., Selcher, J.C., Petraitis, J.J., Trzaskos, J.M., and Sweatt, J.D. (1998). The
21	MAPK cascade is required for mammalian associative learning. Nat Neurosci 1, 602-609.
22	Attramadal, H., Arriza, J.L., Aoki, C., Dawson, T.M., Codina, J., Kwatra, M.M., Snyder, S.H.,
23	Caron, M.G., and Lefkowitz, R.J. (1992). Beta-arrestin2, a novel member of the arrestin/beta-
24	arrestin gene family. J Biol Chem 267, 17882-17890.
25	Austin Zamarripa, C., Edwards, S.R., Qureshi, H.N., Yi, J.N., Blough, B.E., and Freeman,
26	K.B. (2018). The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and
27	antinociceptive effects that are comparable to oxycodone in rats. Drug Alcohol Depend 192,
28	158-162.
29	Barrenha, G.D., and Chester, J.A. (2007). Genetic correlation between innate alcohol
30	preference and fear-potentiated startle in selected mouse lines. Alcohol Clin Exp Res 31,
31	1081-1088.

- 1 Beaulieu, J.M., Sotnikova, T.D., Marion, S., Lefkowitz, R.J., Gainetdinov, R.R., and Caron,
- 2 M.G. (2005). An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic
- 3 neurotransmission and behavior. Cell *122*, 261-273.
- 4 Bjork, K., Rimondini, R., Hansson, A.C., Terasmaa, A., Hyytia, P., Heilig, M., and Sommer,
- 5 W.H. (2008). Modulation of voluntary ethanol consumption by beta-arrestin 2. FASEB J 22,
- 6 2552-2560.
- 7 Bohn, L.M., Gainetdinov, R.R., Lin, F.T., Lefkowitz, R.J., and Caron, M.G. (2000). Mu-
- 8 opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not
- 9 dependence. Nature 408, 720-723.
- 10 Bohn, L.M., Lefkowitz, R.J., Gainetdinov, R.R., Peppel, K., Caron, M.G., and Lin, F.T.
- 11 (1999). Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286, 2495-
- 12 2498.
- Bourin, M., and Hascoet, M. (2003). The mouse light/dark box test. European journal of pharmacology *463*, 55-65.
- 15 Bruchas, M.R., Land, B.B., Aita, M., Xu, M., Barot, S.K., Li, S., and Chavkin, C. (2007).
- 16 Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-
- 17 dependent dysphoria. J Neurosci 27, 11614-11623.
- 18 Bruchas, M.R., Macey, T.A., Lowe, J.D., and Chavkin, C. (2006). Kappa opioid receptor
- 19 activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol
- 20 Chem 281, 18081-18089.
- 21 Cen, B., Yu, Q., Guo, J., Wu, Y., Ling, K., Cheng, Z., Ma, L., and Pei, G. (2001). Direct
- binding of beta-arrestins to two distinct intracellular domains of the delta opioid receptor. J
 Neurochem *76*, 1887-1894.
- 24 Chiang, T., Sansuk, K., and van Rijn, R.M. (2016). beta-Arrestin 2 dependence of delta
- 25 opioid receptor agonists is correlated with alcohol intake. Br J Pharmacol *173*, 332-343.
- 26 Chu Sin Chung, P., Keyworth, H.L., Martin-Garcia, E., Charbogne, P., Darcq, E., Bailey, A.,
- 27 Filliol, D., Matifas, A., Scherrer, G., Ouagazzal, A.M., et al. (2015). A novel anxiogenic role
- 28 for the delta opioid receptor expressed in GABAergic forebrain neurons. Biol Psychiatry 77,
- 29 404-415.
- 30 Conner, D.A., Mathier, M.A., Mortensen, R.M., Christe, M., Vatner, S.F., Seidman, C.E., and
- 31 Seidman, J.G. (1997). beta-Arrestin1 knockout mice appear normal but demonstrate altered
- 32 cardiac responses to beta-adrenergic stimulation. Circ Res 81, 1021-1026.

- 1 Corder, G., Ahanonu, B., Grewe, B.F., Wang, D., Schnitzer, M.J., and Scherrer, G. (2019).
- 2 An amygdalar neural ensemble that encodes the unpleasantness of pain. Science 363, 276-
- 3 281.
- 4 Coyle, J.T., and Duman, R.S. (2003). Finding the intracellular signaling pathways affected by
- 5 mood disorder treatments. Neuron *38*, 157-160.
- 6 David, D.J., Samuels, B.A., Rainer, Q., Wang, J.W., Marsteller, D., Mendez, I., Drew, M.,
- 7 Craig, D.A., Guiard, B.P., Guilloux, J.P., et al. (2009). Neurogenesis-dependent and -
- 8 independent effects of fluoxetine in an animal model of anxiety/depression. Neuron *62*, 4799 493.
- 10 de la Mora, M.P., Gallegos-Cari, A., Arizmendi-Garcia, Y., Marcellino, D., and Fuxe, K.
- 11 (2010). Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and
- 12 anxiety: Structural and functional analysis. Prog Neurobiol 90, 198-216.
- 13 Do-Monte, F.H., Kincheski, G.C., Pavesi, E., Sordi, R., Assreuy, J., and Carobrez, A.P.
- 14 (2010). Role of beta-adrenergic receptors in the ventromedial prefrontal cortex during
- 15 contextual fear extinction in rats. Neurobiol Learn Mem 94, 318-328.
- Eisinger, D.A., Ammer, H., and Schulz, R. (2002). Chronic morphine treatment inhibits
 opioid receptor desensitization and internalization. J Neurosci 22, 10192-10200.
- 18 Erbs, E., Faget, L., Scherrer, G., Matifas, A., Filliol, D., Vonesch, J.L., Koch, M., Kessler, P.,
- 19 Hentsch, D., Birling, M.C., et al. (2015). A mu-delta opioid receptor brain atlas reveals
- 20 neuronal co-occurrence in subcortical networks. Brain Struct Funct 220, 677-702.
- 21 Fadok, J.P., Darvas, M., Dickerson, T.M., and Palmiter, R.D. (2010). Long-term memory for
- 22 pavlovian fear conditioning requires dopamine in the nucleus accumbens and basolateral
- amygdala. PLoS One 5, e12751.
- 24 Fadok, J.P., Dickerson, T.M., and Palmiter, R.D. (2009). Dopamine is necessary for cue-
- 25 dependent fear conditioning. J Neurosci 29, 11089-11097.
- Fanselow, M.S., and Dong, H.W. (2010). Are the dorsal and ventral hippocampus
 functionally distinct structures? Neuron 65, 7-19.
- 28 Felix-Ortiz, A.C., Beyeler, A., Seo, C., Leppla, C.A., Wildes, C.P., and Tye, K.M. (2013).
- 29 BLA to vHPC inputs modulate anxiety-related behaviors. Neuron 79, 658-664.
- 30 File, S.E., Kenny, P.J., and Cheeta, S. (2000). The role of the dorsal hippocampal
- 31 serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol Biochem
- 32 Behav 66, 65-72.
- 33 Goldsmith, Z.G., and Dhanasekaran, D.N. (2007). G protein regulation of MAPK networks.
- 34 Oncogene 26, 3122-3142.

- 1 Gurevich, E.V., Benovic, J.L., and Gurevich, V.V. (2002). Arrestin2 and arrestin3 are
- 2 differentially expressed in the rat brain during postnatal development. Neuroscience 109,
- 3 421-436.
- 4 Gurevich, E.V., Benovic, J.L., and Gurevich, V.V. (2004). Arrestin2 expression selectively
- 5 increases during neural differentiation. J Neurochem 91, 1404-1416.
- 6 Gutkind, J.S. (2000). Regulation of mitogen-activated protein kinase signaling networks by G
- 7 protein-coupled receptors. Sci STKE 2000, re1.
- 8 Hahn, Y.K., Paris, J.J., Lichtman, A.H., Hauser, K.F., Sim-Selley, L.J., Selley, D.E., and
- 9 Knapp, P.E. (2016). Central HIV-1 Tat exposure elevates anxiety and fear conditioned
- 10 responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein
- 11 activation and beta-arrestin 2 activity in the forebrain. Neurobiol Dis 92, 124-136.
- 12 Herry, C., Trifilieff, P., Micheau, J., Luthi, A., and Mons, N. (2006). Extinction of auditory
- fear conditioning requires MAPK/ERK activation in the basolateral amygdala. Eur J
 Neurosci 24, 261-269.
- 15 Hill, R., Disney, A., Conibear, A., Sutcliffe, K., Dewey, W., Husbands, S., Bailey, C., Kelly,
- E., and Henderson, G. (2018). The novel mu-opioid receptor agonist PZM21 depresses
 respiration and induces tolerance to antinociception. Br J Pharmacol *175*, 2653-2661.
- Hoeppner, C.Z., Cheng, N., and Ye, R.D. (2012). Identification of a nuclear localization
 sequence in beta-arrestin-1 and its functional implications. J Biol Chem 287, 8932-8943.
- 20 Huang, B., Li, Y., Cheng, D., He, G., Liu, X., and Ma, L. (2018). beta-Arrestin-biased beta-
- adrenergic signaling promotes extinction learning of cocaine reward memory. Sci Signal 11.
- Janak, P.H., and Tye, K.M. (2015). From circuits to behaviour in the amygdala. Nature *517*,
 284-292.
- 24 Jimenez, J.C., Su, K., Goldberg, A.R., Luna, V.M., Biane, J.S., Ordek, G., Zhou, P., Ong,
- 25 S.K., Wright, M.A., Zweifel, L., et al. (2018). Anxiety Cells in a Hippocampal-Hypothalamic
- 26 Circuit. Neuron 97, 670-683 e676.
- 27 Kang, J., Shi, Y., Xiang, B., Qu, B., Su, W., Zhu, M., Zhang, M., Bao, G., Wang, F., Zhang,
- 28 X., et al. (2005). A nuclear function of beta-arrestin1 in GPCR signaling: regulation of
- 29 histone acetylation and gene transcription. Cell 123, 833-847.
- 30 Kheirbek, M.A., Drew, L.J., Burghardt, N.S., Costantini, D.O., Tannenholz, L., Ahmari, S.E.,
- 31 Zeng, H., Fenton, A.A., and Hen, R. (2013). Differential control of learning and anxiety
- 32 along the dorsoventral axis of the dentate gyrus. Neuron 77, 955-968.


- 1 Kim, J.W., Ko, M.J., Gonzales, E.L., Kang, R.J., Kim, D.G., Kim, Y., Seung, H., Oh, H.A.,
- 2 Eun, P.H., and Shin, C.Y. (2018). Social support rescues acute stress-induced cognitive
- 3 impairments by modulating ERK1/2 phosphorylation in adolescent mice. Sci Rep 8, 12003.
- 4 Kindt, M., Soeter, M., and Vervliet, B. (2009). Beyond extinction: erasing human fear
 5 responses and preventing the return of fear. Nat Neurosci *12*, 256-258.
- 6 Klee, W.A., Simonds, W.F., Sweat, F.W., Burke, T.R., Jr., Jacobson, A.E., and Rice, K.C.
- 7 (1982). Identification of a Mr 58 000 glycoprotein subunit of the opiate receptor. FEBS Lett
- 8 *150*, 125-128.
- 9 Kliewer, A., Schmiedel, F., Sianati, S., Bailey, A., Bateman, J.T., Levitt, E.S., Williams, J.T.,
- 10 Christie, M.J., and Schulz, S. (2019). Phosphorylation-deficient G-protein-biased mu-opioid
- 11 receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat
- 12 Commun 10, 367.
- 13 Ko, M.J., Mulia, G.E., and van Rijn, R.M. (2019). Commonly Used Anesthesia/Euthanasia
- 14 Methods for Brain Collection Differentially Impact MAPK Activity in Male and Female
- 15 C57BL/6 Mice. Front Cell Neurosci 13, 96.
- Kung, J.C., Chen, T.C., Shyu, B.C., Hsiao, S., and Huang, A.C. (2010). Anxiety- and
 depressive-like responses and c-fos activity in preproenkephalin knockout mice:
 oversensitivity hypothesis of enkephalin deficit-induced posttraumatic stress disorder. J
 Biomed Sci 17, 29.
- 20 LaLumiere, R.T., Nawar, E.M., and McGaugh, J.L. (2005). Modulation of memory
- 21 consolidation by the basolateral amygdala or nucleus accumbens shell requires concurrent
- dopamine receptor activation in both brain regions. Learn Mem 12, 296-301.
- 23 Land, B.B., Bruchas, M.R., Schattauer, S., Giardino, W.J., Aita, M., Messinger, D., Hnasko,
- 24 T.S., Palmiter, R.D., and Chavkin, C. (2009). Activation of the kappa opioid receptor in the
- 25 dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc
- 26 Natl Acad Sci U S A 106, 19168-19173.
- 27 Latapy, C., and Beaulieu, J.M. (2013). beta-Arrestins in the central nervous system. Prog Mol
- 28 Biol Transl Sci 118, 267-295.
- Lefkowitz, R.J., and Shenoy, S.K. (2005). Transduction of receptor signals by beta-arrestins.
 Science *308*, 512-517.
- 31 Li, Y., Li, H., Liu, X., Bao, G., Tao, Y., Wu, Z., Xia, P., Wu, C., Li, B., and Ma, L. (2009).
- 32 Regulation of amygdalar PKA by beta-arrestin-2/phosphodiesterase-4 complex is critical for
- 33 fear conditioning. Proc Natl Acad Sci U S A *106*, 21918-21923.


- 1 Lohse, M.J., Benovic, J.L., Codina, J., Caron, M.G., and Lefkowitz, R.J. (1990). beta-
- 2 Arrestin: a protein that regulates beta-adrenergic receptor function. Science 248, 1547-1550.
- 3 Manglik, A., Lin, H., Aryal, D.K., McCorvy, J.D., Dengler, D., Corder, G., Levit, A., Kling,
- 4 R.C., Bernat, V., Hubner, H., et al. (2016). Structure-based discovery of opioid analgesics
- 5 with reduced side effects. Nature *537*, 185-190.
- 6 Mansour, A., Khachaturian, H., Lewis, M.E., Akil, H., and Watson, S.J. (1987).
- 7 Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain
- 8 and midbrain. J Neurosci 7, 2445-2464.
- 9 Massaly, N., Copits, B.A., Wilson-Poe, A.R., Hipolito, L., Markovic, T., Yoon, H.J., Liu, S.,
- 10 Walicki, M.C., Bhatti, D.L., Sirohi, S., et al. (2019). Pain-Induced Negative Affect Is
- 11 Mediated via Recruitment of The Nucleus Accumbens Kappa Opioid System. Neuron 102,
- 12 564-573 e566.
- 13 Melia, K.R., Falls, W.A., and Davis, M. (1992). Involvement of pertussis toxin sensitive G-
- 14 proteins in conditioned fear-potentiated startle: possible involvement of the amygdala. Brain
- 15 Res 584, 141-148.
- 16 Mores, K.L., Cummins, B.R., Cassell, R.J., and van Rijn, R.M. (2019). A Review of the
- 17 Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists. Front18 Pharmacol 10, 407.
- 19 Morgan, M.A., and Pfaff, D.W. (2002). Estrogen's effects on activity, anxiety, and fear in two
- 20 mouse strains. Behav Brain Res 132, 85-93.
- 21 Narita, M., Kaneko, C., Miyoshi, K., Nagumo, Y., Kuzumaki, N., Nakajima, M., Nanjo, K.,
- 22 Matsuzawa, K., Yamazaki, M., and Suzuki, T. (2006). Chronic pain induces anxiety with
- concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology *31*,
- 24 739-750.
- 25 O'Brien, W.T., Huang, J., Buccafusca, R., Garskof, J., Valvezan, A.J., Berry, G.T., and Klein,
- 26 P.S. (2011). Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation
- and lithium-sensitive behaviors in mice. J Clin Invest 121, 3756-3762.
- Paxinos, G., and Franklin, K.B. (2004). The mouse brain in stereotaxic coordinates (Gulf
 professional publishing).
- 30 Perrine, S.A., Hoshaw, B.A., and Unterwald, E.M. (2006). Delta opioid receptor ligands
- 31 modulate anxiety-like behaviors in the rat. Br J Pharmacol *147*, 864-872.
- 32 Pradhan, A.A., Befort, K., Nozaki, C., Gaveriaux-Ruff, C., and Kieffer, B.L. (2011). The
- 33 delta opioid receptor: an evolving target for the treatment of brain disorders. Trends
- 34 Pharmacol Sci 32, 581-590.

- 1 Pradhan, A.A., Perroy, J., Walwyn, W.M., Smith, M.L., Vicente-Sanchez, A., Segura, L.,
- 2 Bana, A., Kieffer, B.L., and Evans, C.J. (2016). Agonist-Specific Recruitment of Arrestin
- 3 Isoforms Differentially Modify Delta Opioid Receptor Function. J Neurosci 36, 3541-3551.
- 4 Raehal, K.M., and Bohn, L.M. (2011). The role of beta-arrestin2 in the severity of
- 5 antinociceptive tolerance and physical dependence induced by different opioid pain
- 6 therapeutics. Neuropharmacology 60, 58-65.
- 7 Raehal, K.M., Walker, J.K., and Bohn, L.M. (2005). Morphine side effects in beta-arrestin 2
- 8 knockout mice. J Pharmacol Exp Ther *314*, 1195-1201.
- 9 Ragnauth, A., Schuller, A., Morgan, M., Chan, J., Ogawa, S., Pintar, J., Bodnar, R.J., and
- 10 Pfaff, D.W. (2001). Female preproenkephalin-knockout mice display altered emotional
- 11 responses. Proc Natl Acad Sci U S A 98, 1958-1963.
- 12 Richards, E.M., Mathews, D.C., Luckenbaugh, D.A., Ionescu, D.F., Machado-Vieira, R.,
- 13 Niciu, M.J., Duncan, W.C., Nolan, N.M., Franco-Chaves, J.A., Hudzik, T., et al. (2016). A
- 14 randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in
- 15 anxious depression. Psychopharmacology (Berl) 233, 1119-1130.
- 16 Robins, M.T., Chiang, T., Berry, J.N., Ko, M.J., Ha, J.E., and van Rijn, R.M. (2018a).
- 17 Behavioral Characterization of beta-Arrestin 1 Knockout Mice in Anxiety-Like and Alcohol
- 18 Behaviors. Front Behav Neurosci 12, 54.
- 19 Robins, M.T., Chiang, T., Mores, K.L., Alongkronrusmee, D., and van Rijn, R.M. (2018b).
- 20 Critical Role for Gi/o-Protein Activity in the Dorsal Striatum in the Reduction of Voluntary
- 21 Alcohol Intake in C57Bl/6 Mice. Front Psychiatry 9, 112.
- 22 Rozenfeld, R., and Devi, L.A. (2007). Receptor heterodimerization leads to a switch in
- 23 signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.
- 24 FASEB J 21, 2455-2465.
- 25 Saitoh, A., Kimura, Y., Suzuki, T., Kawai, K., Nagase, H., and Kamei, J. (2004). Potential
- 26 anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in
- 27 behavioral models in rodents. J Pharmacol Sci 95, 374-380.
- 28 Saitoh, A., Suzuki, S., Soda, A., Ohashi, M., Yamada, M., Oka, J.I., Nagase, H., and Yamada,
- 29 M. (2018). The delta opioid receptor agonist KNT-127 in the prelimbic medial prefrontal
- 30 cortex attenuates veratrine-induced anxiety-like behaviors in mice. Behav Brain Res 336, 77-
- 31 84.
- 32 Shi, Y., Feng, Y., Kang, J., Liu, C., Li, Z., Li, D., Cao, W., Qiu, J., Guo, Z., Bi, E., et al.
- 33 (2007). Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1. Nat
- 34 Immunol *8*, 817-824.


- 1 Solati, J., Zarrindast, M.R., and Salari, A.A. (2010). Dorsal hippocampal opioidergic system
- 2 modulates anxiety-like behaviors in adult male Wistar rats. Psychiatry Clin Neurosci 64, 634-
- 3 641.
- 4 Sugiyama, A., Yamada, M., Furuie, H., Gotoh, L., Saitoh, A., Nagase, H., Oka, J.I., and
- 5 Yamada, M. (2019). Systemic administration of a delta opioid receptor agonist, KNT-127,
- 6 facilitates extinction learning of fear memory in rats. J Pharmacol Sci 139, 174-179.
- 7 Takahashi, L.K. (2001). Role of CRF(1) and CRF(2) receptors in fear and anxiety. Neurosci
- 8 Biobehav Rev 25, 627-636.
- 9 Terburg, D., Scheggia, D., Triana Del Rio, R., Klumpers, F., Ciobanu, A.C., Morgan, B.,
- 10 Montoya, E.R., Bos, P.A., Giobellina, G., van den Burg, E.H., et al. (2018). The Basolateral
- 11 Amygdala Is Essential for Rapid Escape: A Human and Rodent Study. Cell 175, 723-735
- 12 e716.
- 13 Tohgo, A., Pierce, K.L., Choy, E.W., Lefkowitz, R.J., and Luttrell, L.M. (2002). beta-
- 14 Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-
- mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem 277,9429-9436.
- Tovote, P., Fadok, J.P., and Luthi, A. (2015). Neuronal circuits for fear and anxiety. Nat Rev
 Neurosci *16*, 317-331.
- 19 Tye, K.M., Prakash, R., Kim, S.Y., Fenno, L.E., Grosenick, L., Zarabi, H., Thompson, K.R.,
- 20 Gradinaru, V., Ramakrishnan, C., and Deisseroth, K. (2011). Amygdala circuitry mediating
- 21 reversible and bidirectional control of anxiety. Nature *471*, 358-362.
- van Rijn, R.M., Brissett, D.I., and Whistler, J.L. (2010). Dual efficacy of delta opioid
 receptor-selective ligands for ethanol drinking and anxiety. J Pharmacol Exp Ther *335*, 133139.
- 25 Vicente-Sanchez, A., Dripps, I.J., Tipton, A.F., Akbari, H., Akbari, A., Jutkiewicz, E.M., and
- 26 Pradhan, A.A. (2018). Tolerance to high-internalizing delta opioid receptor agonist is
- 27 critically mediated by arrestin 2. Br J Pharmacol 175, 3050-3059.
- 28 Walker, D.L., and Davis, M. (2002). Quantifying fear potentiated startle using absolute
- 29 versus proportional increase scoring methods: implications for the neurocircuitry of fear and
- anxiety. Psychopharmacology (Berl) 164, 318-328.
- 31 Whalen, E.J., Rajagopal, S., and Lefkowitz, R.J. (2011). Therapeutic potential of beta-
- 32 arrestin- and G protein-biased agonists. Trends Mol Med 17, 126-139.


- 1 Zurkovsky, L., Sedaghat, K., Ahmed, M.R., Gurevich, V.V., and Gurevich, E.V. (2017).
- 2 Arrestin-2 and arrestin-3 differentially modulate locomotor responses and sensitization to
- 3 amphetamine. Neuropharmacology 121, 20-29.
- 4





0 min 10 min 30 min











Day 1: Acoustic Startle










Day 3: FPS Testing + Drug Administration








(h)












Con

10 min

TAN67

30 min



SNC80

